about
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approachLaquinimod in the treatment of relapsing remitting multiple sclerosis.Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Imaging as an Outcome Measure in Multiple Sclerosis.Outcome Measures in Clinical Trials for Multiple Sclerosis.Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot studyTwo studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimodCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.Evidence of disease control: a realistic concept beyond NEDA in the treatment of multiple sclerosis.No evidence of disease activity in multiple sclerosis patients.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Critical analysis on the present methods for brain volume measurements in multiple sclerosis.Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis.Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education.Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion.Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis.Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany.Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.[Real-world evidence : Benefits and limitations in multiple sclerosis research].Cannabidiol to Improve Mobility in People with Multiple Sclerosis.Repetitive Transcranial Magnetic Stimulation, Cognition, and Multiple Sclerosis: An Overview.Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
P2860
Q28080043-67AC4B5D-0557-43A3-9ED7-C22FCCCE5E34Q31080085-48C4948D-43C5-4087-B47C-7102FEC46567Q31115496-30152C3D-6503-4FE1-AC2E-47CF21757237Q31134617-2DDE9D58-67D7-4C31-BCAB-EA90D7A6CB6CQ31160866-3CA8EBF5-2D37-4417-95B3-3EF1390D66D4Q33584623-0CC151FD-413F-45C9-B6C4-EAFF303513C1Q33642908-18051449-FD09-4083-826C-A160A41FF1DDQ33736193-64BB0FB0-5EC7-4359-BFAC-6B253F4EC33DQ36097847-FB7129FC-32FF-419F-9917-7A47EEA749ACQ36352813-266C40D9-251A-4BD4-B3F1-0B2B076673C9Q38739510-D5CDE8C0-BF28-49CE-B9ED-1989F480A8B8Q38879765-E1FE4678-FD73-438E-93A9-2F258FB625A9Q39161011-9F390E1C-99F2-4E2B-A542-A549242C2606Q39459514-8291E800-295F-485C-92BA-CDE5566FFE0BQ40129978-E65D73A9-5A31-4611-A07B-85C0D4C98AAFQ41488417-A2F9B450-5735-4742-A27B-7251E58E0EB8Q47926720-3A8D6F90-D5A2-47F9-AC0F-4A2951733587Q47947804-F65EDE07-68A4-482A-9473-B06A34C0B3B1Q49164654-FFC6FEFF-6A04-46EA-8B29-273715F5705FQ49335924-4F48BDB2-1BC9-4165-952C-1F976C0596E9Q53125112-FB639B6F-EF12-4223-85E8-352BF6B63CC6Q54304253-FEE23FE1-272E-44DF-B6FB-48500053A64EQ54967067-8D983C32-8343-4E0D-8679-FDBEF31E88CBQ54985851-4F0D6D9D-F00B-484C-9008-72F80882CF4FQ58729047-3D8EF63E-7FD7-4AEB-8C7E-7F1C1D81410F
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Optimizing treatment success in multiple sclerosis
@ast
Optimizing treatment success in multiple sclerosis
@en
Optimizing treatment success in multiple sclerosis
@nl
type
label
Optimizing treatment success in multiple sclerosis
@ast
Optimizing treatment success in multiple sclerosis
@en
Optimizing treatment success in multiple sclerosis
@nl
prefLabel
Optimizing treatment success in multiple sclerosis
@ast
Optimizing treatment success in multiple sclerosis
@en
Optimizing treatment success in multiple sclerosis
@nl
P2093
P2860
P50
P3181
P1433
P1476
Optimizing treatment success in multiple sclerosis
@en
P2093
Davorka Tomic
Gavin Giovannoni
Sven Schippling
Tim Vollmer
Tobias Derfuss
P2860
P2888
P304
P3181
P356
10.1007/S00415-015-7986-Y
P407
P5008
P577
2015-12-24T00:00:00Z
P5875
P6179
1035869749